title: Treatment of massive acute pulmonary embolism. The use of low doses of intrapulmonary arterial streptokinase combined with full doses of systemic heparin.
abstract: The efficacy of low-dose, locally administered streptokinase (SK) combined with full therapeutic systemic doses of heparin was investigated. Seven patients with angiographically proven massive acute pulmonary embolism were treated. Streptokinase, 10,000-20,000 units/hour, was administered directly into the left or right pulmonary artery for 9 to 24 hours. Heparin was administered concurrently. The number of unperfused segments of the infused lung shown on the lung scan decreased from 5 +/- 2 to 2 +/- 1 after 12-24 hours (p less than .01). No change was shown in the contralateral lung. The angiographic index of severity score in the infused lung decreased from 16 +/- 1 to 9 +/- 4 (p less than .01). The partial pressure of oxygen in arterial blood improved within four hours. In spite of the low doses of streptokinase, however, two major bleeding episodes occurred that required blood transfusion. In conclusion, low dose intrapulmonary streptokinase, combined with intravenous heparin, may provide a therapeutic option in patients with life-threatening massive acute pulmonary embolism in whom full dose lytic therapy may be hazardous, although even low dose lytic therapy was associated with risk.
authors.affiliation: Henry Ford Hospital, Detroit.
authors.forename: K V
authors.initials: KV
authors.lastname: Leeper
authors.forename: J
authors.initials: J
authors.lastname: Popovich
authors.forename: B A
authors.initials: BA
authors.lastname: Lesser
authors.forename: D
authors.initials: D
authors.lastname: Adams
authors.forename: J W
authors.initials: JW
authors.lastname: Froelich
authors.forename: M W
authors.initials: MW
authors.lastname: Burke
authors.forename: P C
authors.initials: PC
authors.lastname: Shetty
authors.forename: J H
authors.initials: JH
authors.lastname: Thrall
authors.forename: P D
authors.initials: PD
authors.lastname: Stein
mesh_terms: D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000502:physiology; D011651:Pulmonary Artery; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D013300:Streptokinase / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D006493:Heparin; D013300:Streptokinase; D010100:Oxygen